FourKites Bolsters its Management Team with Supply Chain Industry Veterans
19.1.2023 11:00:00 EET | Business Wire | Press release
Leading supply chain visibility company FourKites today announces it has strengthened its executive team with the appointment of a Chief Strategy Officer and a Vice President of Global Customer Success. FourKites’ leadership position, rapid growth and momentum in the supply chain visibility market continue to make it a destination for top talent in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005040/en/
FourKites Bolsters its Management Team with Supply Chain Industry Veterans (Photo: Business Wire)
Fabrizio (Fab) Brasca has been promoted to FourKites Chief Strategy Officer. Brasca joined FourKites last year as EVP, Industry and Market Strategy. As Chief Strategy Officer, he will continue to lead the company’s Industry teams and take on expanded responsibilities including the strategy for FourKites’ Global Alliances division and leadership of the customer value engineering and pre-sales functions.
Additionally, Rebecca Nerad joined FourKites as Vice President of Global Customer Success. Nerad has over 20 years of experience in the supply chain industry, holding customer success roles for companies such as i2 Technologies, JDA Software and Bristlecone. Most recently, she served as Vice President of Customer Success at e2open, maximising solution adoption, expansion and retention. Nerad and her team will remain focused on building strong relationships and driving value with customers as FourKites expands.
“Fab has played a pivotal role in establishing FourKites’ industry team and building a vertical go-to-market strategy. His industry knowledge and partnership with customers will serve him well as he helps FourKites develop and execute its strategy more broadly,” says FourKites founder and CEO Mathew Elenjickal. “And Rebecca is a remarkable talent and a great fit for our culture, where we pride ourselves on true partnership with our customers. I look forward to working with both of them, as we continue toward our goal of helping customers achieve 100% visibility everywhere.”
FourKites continues to attract top-level talent from the industry as it gains recognition as a great place to work and a pioneering innovator in the real-time visibility market. This month, FourKites was named to Built In’s list of Best Places to Work in Chicago for the third consecutive year, and it has been named a Great Place to Work in India by the Great Places Institute for five consecutive years. The company has been recognised for its ability to solve the complex pain points of enterprise customers, having been named a Leader in Gartner’s Magic Quadrant for Real-time Transportation Visibility Platforms for its ability to execute, and with the highest completeness of vision. FourKites also scored the highest for Fortune 500 businesses with complex needs, according to Gartner’s Critical Capabilities for Real-Time Transportation Visibility Platforms report. Other accolades include Inc. Magazine’s Best in Business list in the Logistics & Transportation category, AI Trailblazer by Everest Group, the 2022 Top Food Chain Technology providers, Top Green Provider, and BlueYonder's GTM Partner of the Year in 2022.
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005040/en/
Contact information
Scott Johnston
European PR Director, FourKites
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom